Assessment of dyslipidemia management in Turkey using a Delphi panel

This study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines. Addressing these gaps could lead to more effective management of dyslipidemia and reduce the burden of cardiovascular disease in Turkey. The study's insights provide critical recommendations for clinicians and policymakers to improve clinical practice and health outcomes through more aggressive lipid-lowering strategies.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2024-12-28
DOI
https://doi.org/10.1038/s41598-024-82780-2
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessment of dyslipidemia management in Turkey using a Delphi panel

Öner Özdoğan, Meral Kayıkçıoğlu, Ahmet Temizhan, Lâle Tokgözoğlu et al.
1 links
Scientific Reports
Lipoproteins and Cardiovascular Health
article

Assessment of dyslipidemia management in Turkey using a Delphi panel

Öner Özdoğan, Meral Kayıkçıoğlu, Ahmet Temizhan, Lâle Tokgözoğlu, Uygar Çağdaş Yüksel, Barış Güngör, Ümit Yaşar Si̇nan, Tuğba Kemaloğlu Öz, Mehmet Birhan Yılmaz, Mesut Kus
article en

Abstract

This study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines. Addressing these gaps could lead to more effective management of dyslipidemia and reduce the burden of cardiovascular disease in Turkey. The study's insights provide critical recommendations for clinicians and policymakers to improve clinical practice and health outcomes through more aggressive lipid-lowering strategies.

Scientific ReportsVol. 14(1)
Izmir University (TR), Dokuz Eylül University (TR), Ege University (TR), Haseki Eğitim ve Araştırma Hastanesi (TR), Istanbul University-Cerrahpaşa (TR), Istinye University (TR), Sağlık Bilimleri Üniversitesi (TR), Liv Hospital (TR), Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi (TR), Hacettepe University (TR), Istanbul University (TR)
Novartis Pharma
Zero hunger
Openalex Percentile: Top 55%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.